CareerExamPro

RAPS Regulatory Affairs Certification — Devices (RAC-Devices) practice test

17 practice questions for this exam, each with a full explanation and cited rule or blueprint reference.

Start practising

RAPS RAC, ACRP/SOCRA, MPJE & ASQ CQE: practice drill

10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.

Timed mock exam

17 questions in 20 minutes, drawn from every topic. No answers shown until the end, then a full score breakdown, your weakest topics and a review of what you missed.

Practice tests that prepare you for this exam

Practise by topic

About this exam

Agency / Issuer
RAPS
Region
Global / Online

Exact question counts, passing scores, and allowed reference materials vary by testing window and state/agency. Always confirm current rules with the official testing provider.

Sample questions

A medical device manufacturer develops a novel noninvasive optical sensor designed to screen for peripheral arterial disease in outpatient clinics. A thorough search of FDA databases confirms that no legally marketed predicate device exists, yet the company's risk analysis indicates that general and special controls will provide reasonable assurance of safety and effectiveness. Which FDA premarket submission pathway is most appropriate?

  1. A Traditional 510(k) citing a Class II pulse oximeter as a split predicate and proposing bench testing for the new intended use.
  2. A Premarket Approval (PMA) application, because every novel device without a predicate must complete Class III clinical review.
  3. A De Novo classification request to create a new Class I or Class II device type usable as a predicate.
  4. A Humanitarian Device Exemption (HDE), because lacking a legally marketed predicate exempts the sensor from effectiveness evidence.
Show the answer

C. A De Novo classification request to create a new Class I or Class II device type usable as a predicate.

Under FDCA Section 513(f)(2) and 21 CFR Part 860 Subpart D, novel devices lacking a legally marketed predicate are automatically classified into Class III by statute, but low-to-moderate risk devices for which general controls alone (Class I) or general and special controls (Class II) provide reasonable assurance of safety and effectiveness may use the De Novo classification pathway. A granted De Novo creates a new classification regulation and allows the device to serve as a predicate for future 510(k) submissions. Split predicates with different intended uses are not permitted under 510(k), and HDE requires a rare disease/condition affecting fewer than 8,000 individuals per year in the US.

Reference: FDCA § 513(f)(2) / 21 CFR Part 860 Subpart D (De Novo Classification Process)

A medical catheter extrusion line operates in statistical control with a normal output distribution for outer diameter. Engineering specifications and process parameters are:

TEXT
Specification Limits : 10.00 ± 0.30 mm  (LSL = 9.70 mm, USL = 10.30 mm)
Process Mean (mu)    : 10.06 mm
Process Std Dev (s)  : 0.05 mm

What are the process capability indices Cp and Cpk, and what do they indicate about the extrusion process?

  1. Cp = 2.00 and Cpk = 2.40, showing that the upward mean shift raises actual capability above Cp.
  2. Cp = 1.00 and Cpk = 0.80, showing that process spread equals tolerance width and requires sorting.
  3. Cp = 1.60 and Cpk = 2.00, showing that process spread exceeds tolerance despite accurate centering.
  4. Cp = 2.00 and Cpk = 1.60, showing strong capability slightly lowered by an upward mean shift.
Show the answer

D. Cp = 2.00 and Cpk = 1.60, showing strong capability slightly lowered by an upward mean shift.

Potential capability Cp = (USL - LSL) / (6 * sigma) = (10.30 - 9.70) / (6 * 0.05) = 0.60 / 0.30 = 2.00. Actual capability Cpk = min((USL - mu)/(3 * sigma), (mu - LSL)/(3 * sigma)) = min((10.30 - 10.06)/0.15, (10.06 - 9.70)/0.15) = min(0.24/0.15, 0.36/0.15) = min(1.60, 2.40) = 1.60. By definition Cpk <= Cp; here, Cp = 2.00 > Cpk = 1.60 confirms that the process has tight inherent dispersion but is shifted 0.06 mm above nominal toward the USL.

Reference: ASQ Certified Quality Engineer (CQE) Body of Knowledge — Process Capability (Cp & Cpk)

On Monday morning, a Class II infusion pump manufacturer becomes aware of a firmware defect across an entire distributed lot that causes unintended rapid bolus delivery, requiring immediate remedial action to prevent an unreasonable risk of substantial harm to the public health. No deaths have been reported yet. Under 21 CFR Part 803 (Medical Device Reporting), what is the mandatory FDA reporting timeline?

  1. Submit an electronic MDR within 30 calendar days, because 5-day reporting applies only after a confirmed fatality.
  2. Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.
  3. Submit a written safety report within 15 calendar days under the expedited timeline governing IND drug applications.
  4. Submit an annual summary MDR report at fiscal year-end, provided a field safety notice is sent to hospitals within 10 business days.
Show the answer

B. Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.

Under 21 CFR 803.53(a), a device manufacturer must submit a 5-day Medical Device Report (MDR) to FDA no later than 5 work days after becoming aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health (or after receiving a written FDA request for a 5-day report). Standard death, serious injury, and reportable malfunction MDRs that do not require immediate remedial action are due within 30 calendar days under 21 CFR 803.50.

Reference: 21 CFR 803.50 & 21 CFR 803.53 (FDA Medical Device Reporting Timelines)

Taking this exam soon?

Tell us which exam domains or calculation drills you want more practice on.

Other Biopharma Regulatory & Quality exams